110 related articles for article (PubMed ID: 21440362)
1. Molecular mechanism of action for reversible P2Y12 antagonists.
Liu H; Ge H; Peng Y; Xiao P; Xu J
Biophys Chem; 2011 May; 155(2-3):74-81. PubMed ID: 21440362
[TBL] [Abstract][Full Text] [Related]
2. Docking-based virtual screening of potential human P2Y12 receptor antagonists.
Chen H; Dong X; Zhou M; Shi H; Luo X
Acta Biochim Biophys Sin (Shanghai); 2011 May; 43(5):400-8. PubMed ID: 21474491
[TBL] [Abstract][Full Text] [Related]
3. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
[TBL] [Abstract][Full Text] [Related]
4. Investigating the binding mechanism of novel 6-aminonicotinate-based antagonists with P2Y
Zhou S; Fang D; Tan S; Lin W; Wu W; Zheng K
J Biomol Struct Dyn; 2017 Oct; 35(13):2938-2965. PubMed ID: 27634290
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
[No Abstract] [Full Text] [Related]
6. Functional interaction between purinergic receptors: effect of ligands for A2A and P2Y12 receptors on P2Y1 receptor function.
Suzuki T; Obara Y; Moriya T; Nakata H; Nakahata N
FEBS Lett; 2011 Dec; 585(24):3978-84. PubMed ID: 22079667
[TBL] [Abstract][Full Text] [Related]
7. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information.
Paoletta S; Sabbadin D; von Kügelgen I; Hinz S; Katritch V; Hoffmann K; Abdelrahman A; Straßburger J; Baqi Y; Zhao Q; Stevens RC; Moro S; Müller CE; Jacobson KA
J Comput Aided Mol Des; 2015 Aug; 29(8):737-56. PubMed ID: 26194851
[TBL] [Abstract][Full Text] [Related]
8. Prediction of P2Y12 antagonists using a novel genetic algorithm-support vector machine coupled approach.
Hao M; Li Y; Wang Y; Zhang S
Anal Chim Acta; 2011 Mar; 690(1):53-63. PubMed ID: 21414436
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
[TBL] [Abstract][Full Text] [Related]
10. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions.
Rauch BH; Rosenkranz AC; Ermler S; Böhm A; Driessen J; Fischer JW; Sugidachi A; Jakubowski JA; Schrör K
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2434-42. PubMed ID: 21071695
[TBL] [Abstract][Full Text] [Related]
11. Structure of the human P2Y₁₂ receptor in complex with an antithrombotic drug.
Du B; Liu M
Sci China Life Sci; 2014 Jun; 57(6):645-6. PubMed ID: 24801571
[No Abstract] [Full Text] [Related]
12. Agonist-bound structure of the human P2Y12 receptor.
Zhang J; Zhang K; Gao ZG; Paoletta S; Zhang D; Han GW; Li T; Ma L; Zhang W; Müller CE; Yang H; Jiang H; Cherezov V; Katritch V; Jacobson KA; Stevens RC; Wu B; Zhao Q
Nature; 2014 May; 509(7498):119-22. PubMed ID: 24784220
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor.
Deflorian F; Jacobson KA
J Comput Aided Mol Des; 2011 Apr; 25(4):329-38. PubMed ID: 21461952
[TBL] [Abstract][Full Text] [Related]
14. Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
Zech G; Hessler G; Evers A; Weiss T; Florian P; Just M; Czech J; Czechtizky W; Görlitzer J; Ruf S; Kohlmann M; Nazaré M
J Med Chem; 2012 Oct; 55(20):8615-29. PubMed ID: 22984835
[TBL] [Abstract][Full Text] [Related]
15. Identification and analysis of functionally important amino acids in human purinergic 12 receptor using a Saccharomyces cerevisiae expression system.
Ignatovica V; Megnis K; Lapins M; Schiöth HB; Klovins J
FEBS J; 2012 Jan; 279(1):180-91. PubMed ID: 22044483
[TBL] [Abstract][Full Text] [Related]
16. Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12.
Schmidt P; Ritscher L; Dong EN; Hermsdorf T; Cöster M; Wittkopf D; Meiler J; Schöneberg T
Mol Pharmacol; 2013 Jan; 83(1):256-66. PubMed ID: 23093496
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.
Zhan C; Yang J; Dong XC; Wang YL
J Mol Graph Model; 2007 Jul; 26(1):20-31. PubMed ID: 17110146
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
Tu W; Fan J; Zhang H; Xu G; Liu Z; Qu J; Yang F; Zhang L; Luan T; Yuan J; Gong A; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2014 Jan; 24(1):141-6. PubMed ID: 24332627
[TBL] [Abstract][Full Text] [Related]
19. State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.
Zetterberg F; Svensson P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2739-2754. PubMed ID: 27133596
[TBL] [Abstract][Full Text] [Related]
20. P2Y
Al-Najjar BO; Saqallah FG; Abbas MA; Al-Hijazeen SZ; Sibai OA
Eur J Med Chem; 2022 Jan; 227():113924. PubMed ID: 34731765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
